drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB09020 | DB09330 | 28 | 985 | [
"DDInter212",
"DDInter1352"
] | Bisacodyl | Osimertinib | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
28,
24,
985
]
],
[
[
28,
63,
1181
],
[
1181,
24,
985
]
],
[
[
28,
24,
1383
],
[
1383,
63,
985
]
],
[
[
28,
24,
286
],
[
286,
24,... | [
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and S... |
DB11837 | DB14881 | 1,297 | 180 | [
"DDInter1351",
"DDInter1329"
] | Osilodrostat | Oliceridine | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1297,
24,
180
]
],
[
[
1297,
62,
112
],
[
112,
23,
180
]
],
[
[
1297,
63,
401
],
[
401,
24,
180
]
],
[
[
1297,
24,
124
],
[
124,
... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Promethazine a... |
DB00877 | DB01141 | 629 | 692 | [
"DDInter1678",
"DDInter1208"
] | Sirolimus | Micafungin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. | Moderate | 1 | [
[
[
629,
24,
692
]
],
[
[
629,
21,
28935
],
[
28935,
60,
692
]
],
[
[
629,
24,
351
],
[
351,
63,
692
]
],
[
[
629,
64,
1287
],
[
1287,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Micafungin"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperbilirubinaemia"
],
[
"Hyperbilirubinaemia",
"{u} (Si... | Sirolimus (Compound) causes Hyperbilirubinaemia (Side Effect) and Hyperbilirubinaemia (Side Effect) is caused by Micafungin (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when ... |
DB00427 | DB00962 | 1,233 | 1,639 | [
"DDInter1879",
"DDInter1957"
] | Triprolidine | Zaleplon | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
1233,
24,
1639
]
],
[
[
1233,
24,
13
],
[
13,
24,
1639
]
],
[
[
1233,
24,
1609
],
[
1609,
63,
1639
]
],
[
[
1233,
63,
1242
],
[
1242,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyveri... |
DB00889 | DB09472 | 1,133 | 1,383 | [
"DDInter840",
"DDInter1693"
] | Granisetron | Sodium sulfate | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1133,
24,
1383
]
],
[
[
1133,
24,
609
],
[
609,
24,
1383
]
],
[
[
1133,
25,
643
],
[
643,
24,
1383
]
],
[
[
1133,
63,
521
],
[
521,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Granisetron may lead to a major life threatening interaction when taken with Desvenlafaxine and Des... |
DB01410 | DB06448 | 423 | 171 | [
"DDInter376",
"DDInter1087"
] | Ciclesonide (nasal) | Lonafarnib | Ciclesonide is an organic molecular entity. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
423,
24,
171
]
],
[
[
423,
1,
1351
],
[
1351,
24,
171
]
],
[
[
423,
40,
891
],
[
891,
24,
171
]
],
[
[
423,
64,
1064
],
[
1064,
... | [
[
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Ciclesonide",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a mod... | Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Ciclesonide (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Ciclesonide (Compound) resembles Prednisolone (Compoun... |
DB00773 | DB01149 | 896 | 851 | [
"DDInter702",
"DDInter1274"
] | Etoposide | Nefazodone | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
896,
24,
851
]
],
[
[
896,
6,
8374
],
[
8374,
45,
851
]
],
[
[
896,
7,
3677
],
[
3677,
46,
851
]
],
[
[
896,
18,
6718
],
[
6718,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Etoposide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Etoposide (Compound) upregulates NFKBIE (Gene) and NFKBIE (Gene) is upregulated by Nefazodone (Compound)
Etoposide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Nefazodone (Compound)
Etoposide (Comp... |
DB06228 | DB06273 | 792 | 980 | [
"DDInter1609",
"DDInter1824"
] | Rivaroxaban | Tocilizumab | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
792,
24,
980
]
],
[
[
792,
63,
1461
],
[
1461,
23,
980
]
],
[
[
792,
63,
336
],
[
336,
24,
980
]
],
[
[
792,
64,
1047
],
[
1047,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedip... |
DB04868 | DB11853 | 478 | 230 | [
"DDInter1293",
"DDInter1577"
] | Nilotinib | Relugolix | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
478,
25,
230
]
],
[
[
478,
25,
129
],
[
129,
23,
230
]
],
[
[
478,
24,
1094
],
[
1094,
23,
230
]
],
[
[
478,
62,
112
],
[
112,
2... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} ... | Nilotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause... |
DB06688 | DB15762 | 1,430 | 725 | [
"DDInter1677",
"DDInter1644"
] | Sipuleucel-T | Satralizumab | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
1430,
24,
725
]
],
[
[
1430,
24,
1362
],
[
1362,
24,
725
]
],
[
[
1430,
63,
372
],
[
372,
24,
725
]
],
[
[
1430,
63,
1066
],
[
1066,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clo... |
DB00445 | DB01069 | 322 | 401 | [
"DDInter655",
"DDInter1533"
] | Epirubicin | Promethazine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
322,
24,
401
]
],
[
[
322,
24,
1264
],
[
1264,
63,
401
]
],
[
[
322,
24,
1236
],
[
1236,
24,
401
]
],
[
[
322,
21,
28709
],
[
28709,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbama... |
DB00095 | DB00515 | 66 | 589 | [
"DDInter623",
"DDInter387"
] | Efalizumab | Cisplatin | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
66,
24,
589
]
],
[
[
66,
24,
949
],
[
949,
63,
589
]
],
[
[
66,
63,
58
],
[
58,
24,
589
]
],
[
[
66,
24,
168
],
[
168,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid an... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Efalizumab ma... |
DB00019 | DB09570 | 1,257 | 1,480 | [
"DDInter1405",
"DDInter1002"
] | Pegfilgrastim | Ixazomib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
1257,
24,
1480
]
],
[
[
1257,
24,
268
],
[
268,
24,
1480
]
],
[
[
1257,
24,
110
],
[
110,
63,
1480
]
],
[
[
1257,
63,
1451
],
[
1451,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00692 | DB00780 | 274 | 551 | [
"DDInter1448",
"DDInter1440"
] | Phentolamine | Phenelzine | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
274,
24,
551
]
],
[
[
274,
24,
1161
],
[
1161,
40,
551
]
],
[
[
274,
21,
28827
],
[
28827,
60,
551
]
],
[
[
274,
63,
999
],
[
999,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Phentolamine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Phenelzine (Compound)
Phentolamine... |
DB01166 | DB08896 | 477 | 292 | [
"DDInter379",
"DDInter1576"
] | Cilostazol | Regorafenib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
477,
25,
292
]
],
[
[
477,
63,
79
],
[
79,
1,
292
]
],
[
[
477,
6,
8374
],
[
8374,
45,
292
]
],
[
[
477,
21,
28890
],
[
28890,
6... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib"... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound)
Cilostazol (Compound) causes Myocardial infarction (Side Effect) a... |
DB00015 | DB06603 | 582 | 39 | [
"DDInter1585",
"DDInter1387"
] | Reteplase | Panobinostat | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
582,
25,
39
]
],
[
[
582,
24,
578
],
[
578,
63,
39
]
],
[
[
582,
24,
383
],
[
383,
24,
39
]
],
[
[
582,
25,
4
],
[
4,
24,
... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate ... |
DB00987 | DB14444 | 1,224 | 151 | [
"DDInter460",
"DDInter924"
] | Cytarabine | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1224,
24,
151
]
],
[
[
1224,
63,
66
],
[
66,
24,
151
]
],
[
[
1224,
24,
850
],
[
850,
24,
151
]
],
[
[
1224,
25,
375
],
[
375,
2... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could e... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Cytarabine may cause a moderate inter... |
DB04908 | DB09280 | 1,671 | 1,604 | [
"DDInter741",
"DDInter1101"
] | Flibanserin | Lumacaftor | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
1671,
25,
1604
]
],
[
[
1671,
63,
379
],
[
379,
24,
1604
]
],
[
[
1671,
24,
1281
],
[
1281,
24,
1604
]
],
[
[
1671,
23,
1135
],
[
1135... | [
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabepra... | Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and L... |
DB00945 | DB09564 | 1,479 | 1,296 | [
"DDInter20",
"DDInter930"
] | Acetylsalicylic acid | Insulin degludec | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1479,
24,
1296
]
],
[
[
1479,
62,
17
],
[
17,
24,
1296
]
],
[
[
1479,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1479,
63,
217
],
[
217,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sot... | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tol... |
DB00224 | DB09049 | 215 | 1,135 | [
"DDInter917",
"DDInter1261"
] | Indinavir | Naloxegol | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
215,
25,
1135
]
],
[
[
215,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
215,
24,
1424
],
[
1424,
23,
1135
]
],
[
[
215,
25,
478
],
[
478,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may ca... | Indinavir may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor inter... |
DB06589 | DB08932 | 1,250 | 1,398 | [
"DDInter1400",
"DDInter1111"
] | Pazopanib | Macitentan | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
1250,
24,
1398
]
],
[
[
1250,
6,
8374
],
[
8374,
45,
1398
]
],
[
[
1250,
21,
29429
],
[
29429,
60,
1398
]
],
[
[
1250,
24,
283
],
[
28... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Pazopanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound)
Pazopanib (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Macitentan (Compound)
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib... |
DB00176 | DB00741 | 529 | 167 | [
"DDInter770",
"DDInter885"
] | Fluvoxamine | Hydrocortisone | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
529,
24,
167
]
],
[
[
529,
24,
1220
],
[
1220,
40,
167
]
],
[
[
529,
24,
870
],
[
870,
1,
167
]
],
[
[
529,
6,
8374
],
[
8374,
4... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles ... |
DB01259 | DB11796 | 392 | 1,612 | [
"DDInter1024",
"DDInter786"
] | Lapatinib | Fostemsavir | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
392,
24,
1612
]
],
[
[
392,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
392,
24,
98
],
[
98,
23,
1612
]
],
[
[
392,
24,
1476
],
[
1476,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem a... |
DB00196 | DB00916 | 600 | 112 | [
"DDInter743",
"DDInter1202"
] | Fluconazole | Metronidazole | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
600,
23,
112
]
],
[
[
600,
6,
8374
],
[
8374,
45,
112
]
],
[
[
600,
21,
28692
],
[
28692,
60,
112
]
],
[
[
600,
24,
847
],
[
847,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Fluconazole (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00372 | DB06207 | 999 | 910 | [
"DDInter1793",
"DDInter1667"
] | Thiethylperazine | Silodosin | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Moderate | 1 | [
[
[
999,
24,
910
]
],
[
[
999,
24,
1264
],
[
1264,
24,
910
]
],
[
[
999,
24,
1450
],
[
1450,
63,
910
]
],
[
[
999,
63,
475
],
[
475,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Silodosin
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin an... |
DB00916 | DB01267 | 112 | 519 | [
"DDInter1202",
"DDInter1381"
] | Metronidazole | Paliperidone | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Minor | 0 | [
[
[
112,
23,
519
]
],
[
[
112,
62,
1664
],
[
1664,
1,
519
]
],
[
[
112,
23,
924
],
[
924,
1,
519
]
],
[
[
112,
6,
8374
],
[
8374,
45... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paliperidone"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risperidone"
],
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (... |
DB00065 | DB01281 | 581 | 881 | [
"DDInter923",
"DDInter5"
] | Infliximab | Abatacept | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Major | 2 | [
[
[
581,
25,
881
]
],
[
[
581,
23,
1193
],
[
1193,
62,
881
]
],
[
[
581,
23,
1461
],
[
1461,
23,
881
]
],
[
[
581,
25,
4
],
[
4,
63,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abatacept"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Abatacept
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB00294 | DB11986 | 1,336 | 484 | [
"DDInter701",
"DDInter648"
] | Etonogestrel | Entrectinib | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1336,
24,
484
]
],
[
[
1336,
40,
1197
],
[
1197,
24,
484
]
],
[
[
1336,
24,
1320
],
[
1320,
24,
484
]
],
[
[
1336,
25,
927
],
[
927,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Etonogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
],
[
"Norethisterone",
"{u} may ca... | Etonogestrel (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction t... |
DB00402 | DB00902 | 1,407 | 104 | [
"DDInter685",
"DDInter1168"
] | Eszopiclone | Methdilazine | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1407,
24,
104
]
],
[
[
1407,
24,
13
],
[
13,
24,
104
]
],
[
[
1407,
24,
820
],
[
820,
1,
104
]
],
[
[
1407,
24,
537
],
[
537,
40... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazi... |
DB01065 | DB12015 | 43 | 1,033 | [
"DDInter1142",
"DDInter53"
] | Melatonin | Alpelisib | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice g... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
43,
24,
1033
]
],
[
[
43,
24,
1510
],
[
1510,
24,
1033
]
],
[
[
43,
63,
126
],
[
126,
24,
1033
]
],
[
[
43,
24,
1619
],
[
1619,
... | [
[
[
"Melatonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Melatonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
... | Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfa... |
DB00835 | DB09272 | 100 | 412 | [
"DDInter245",
"DDInter632"
] | Brompheniramine | Eluxadoline | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
100,
24,
412
]
],
[
[
100,
63,
1594
],
[
1594,
24,
412
]
],
[
[
100,
24,
543
],
[
543,
24,
412
]
],
[
[
100,
35,
849
],
[
849,
2... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide... |
DB00220 | DB00641 | 798 | 467 | [
"DDInter1276",
"DDInter1675"
] | Nelfinavir | Simvastatin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Major | 2 | [
[
[
798,
25,
467
]
],
[
[
798,
6,
8374
],
[
8374,
45,
467
]
],
[
[
798,
7,
6717
],
[
6717,
46,
467
]
],
[
[
798,
18,
15501
],
[
15501,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Simvas... | Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simvastatin (Compound)
Nelfinavir (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Simvastatin (Compound)
Nelfinavir (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Simvastatin (Compound)
Nelfi... |
DB00775 | DB01050 | 1,226 | 848 | [
"DDInter1818",
"DDInter900"
] | Tirofiban | Ibuprofen | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1226,
24,
848
]
],
[
[
1226,
21,
29316
],
[
29316,
60,
848
]
],
[
[
1226,
23,
297
],
[
297,
62,
848
]
],
[
[
1226,
63,
831
],
[
831,
... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Tirofiban",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by... | Tirofiban (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Ibuprofen (Compound)
Tirofiban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Tirofiban may ca... |
DB00400 | DB01076 | 353 | 700 | [
"DDInter843",
"DDInter133"
] | Griseofulvin | Atorvastatin | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
353,
24,
700
]
],
[
[
353,
6,
8374
],
[
8374,
45,
700
]
],
[
[
353,
18,
15501
],
[
15501,
57,
700
]
],
[
[
353,
25,
303
],
[
303,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atorvastatin (Compound)
Griseofulvin (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Atorvastatin (Compound)
Griseofulvin may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate an... |
DB08820 | DB13179 | 1,478 | 68 | [
"DDInter997",
"DDInter1882"
] | Ivacaftor | Troleandomycin | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
1478,
25,
68
]
],
[
[
1478,
63,
1601
],
[
1601,
23,
68
]
],
[
[
1478,
63,
309
],
[
309,
24,
68
]
],
[
[
1478,
24,
710
],
[
710,
... | [
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
],
[
"Loratadi... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabe... |
DB00220 | DB00619 | 798 | 1,419 | [
"DDInter1276",
"DDInter909"
] | Nelfinavir | Imatinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
798,
24,
1419
]
],
[
[
798,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
798,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
798,
23,
222
],
[
222,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nelfinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Nelfinavir (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibut... |
DB00188 | DB00912 | 168 | 473 | [
"DDInter222",
"DDInter1581"
] | Bortezomib | Repaglinide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
168,
24,
473
]
],
[
[
168,
6,
3486
],
[
3486,
45,
473
]
],
[
[
168,
21,
30513
],
[
30513,
60,
473
]
],
[
[
168,
24,
798
],
[
798,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Bortezomib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Bortezomib (Compound) causes Ischaemia (Side Effect) and Ischaemia (Side Effect) is caused by Repaglinide (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Ne... |
DB01177 | DB01208 | 77 | 945 | [
"DDInter904",
"DDInter1705"
] | Idarubicin | Sparfloxacin | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
77,
25,
945
]
],
[
[
77,
62,
739
],
[
739,
1,
945
]
],
[
[
77,
64,
1176
],
[
1176,
1,
945
]
],
[
[
77,
63,
1539
],
[
1539,
1,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomeflox... | Idarubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Idarubicin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Idaru... |
DB00675 | DB11979 | 888 | 1,320 | [
"DDInter1744",
"DDInter625"
] | Tamoxifen | Elagolix | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
888,
24,
1320
]
],
[
[
888,
25,
271
],
[
271,
23,
1320
]
],
[
[
888,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
888,
24,
1297
],
[
1297,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
... | Tamoxifen may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a mi... |
DB08880 | DB15822 | 1,510 | 69 | [
"DDInter1771",
"DDInter1504"
] | Teriflunomide | Pralsetinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Major | 2 | [
[
[
1510,
25,
69
]
],
[
[
1510,
25,
283
],
[
283,
24,
69
]
],
[
[
1510,
64,
1213
],
[
1213,
24,
69
]
],
[
[
1510,
24,
124
],
[
124,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pralsetinib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
... | Teriflunomide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Teriflunomide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate... |
DB01234 | DB04845 | 1,220 | 309 | [
"DDInter513",
"DDInter1001"
] | Dexamethasone | Ixabepilone | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
1220,
24,
309
]
],
[
[
1220,
10,
11579
],
[
11579,
44,
309
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1220,
21,
28931
],
[
289... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Dexamethasone",
"{u} (Compound) palliates {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Diseas... | Dexamethasone (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Ixabepilone (Compound)
Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Dexamethasone (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused ... |
DB01249 | DB04861 | 258 | 1,592 | [
"DDInter958",
"DDInter1271"
] | Iodixanol | Nebivolol | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
258,
24,
1592
]
],
[
[
258,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
258,
64,
1274
],
[
1274,
24,
1592
]
],
[
[
258,
63,
1648
],
[
1648... | [
[
[
"Iodixanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Iodixanol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by... | Iodixanol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Iodixanol may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
Iodixanol may... |
DB04844 | DB08865 | 843 | 1,593 | [
"DDInter1778",
"DDInter448"
] | Tetrabenazine | Crizotinib | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
843,
25,
1593
]
],
[
[
843,
7,
3771
],
[
3771,
57,
1593
]
],
[
[
843,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
843,
1,
479
],
[
479,
... | [
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Tetrabenazine",
"{u} (Compound) upregulates {v} (Gene)",
"SUV39H1"
],
[
"SUV39H1",
"{u} (Gene) is downregulated by {v} (Comp... | Tetrabenazine (Compound) upregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Crizotinib (Compound)
Tetrabenazine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Tetrabenazine (Compound) resembles Donepezil (Compound) and Donepezil may cause a minor inte... |
DB01098 | DB06414 | 14 | 655 | [
"DDInter1622",
"DDInter703"
] | Rosuvastatin | Etravirine | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
14,
24,
655
]
],
[
[
14,
6,
6017
],
[
6017,
45,
655
]
],
[
[
14,
21,
28680
],
[
28680,
60,
655
]
],
[
[
14,
63,
168
],
[
168,
23... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Rosuvastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etravirine (Compound)
Rosuvastatin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezom... |
DB00331 | DB00812 | 1,645 | 998 | [
"DDInter1164",
"DDInter1451"
] | Metformin | Phenylbutazone | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
1645,
24,
998
]
],
[
[
1645,
63,
362
],
[
362,
1,
998
]
],
[
[
1645,
24,
97
],
[
97,
40,
998
]
],
[
[
1645,
7,
7273
],
[
7273,
4... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbutazone (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) resembles Phenylbutazone (Compound... |
DB00959 | DB01018 | 1,486 | 1,364 | [
"DDInter1191",
"DDInter847"
] | Methylprednisolone | Guanfacine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
1486,
24,
1364
]
],
[
[
1486,
63,
1512
],
[
1512,
1,
1364
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
1364
]
],
[
[
1486,
21,
28757
],
[
287... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanfacine (Compound)
Methylprednisolone (Compound) causes Dyspepsia (Si... |
DB00500 | DB06209 | 24 | 256 | [
"DDInter1831",
"DDInter1508"
] | Tolmetin | Prasugrel | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
24,
25,
256
]
],
[
[
24,
21,
28649
],
[
28649,
60,
256
]
],
[
[
24,
23,
752
],
[
752,
23,
256
]
],
[
[
24,
63,
305
],
[
305,
24,... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Tolmetin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal haemorrhage"
],
[
"Gastrointestinal haemorrhage",
"{u} (Si... | Tolmetin (Compound) causes Gastrointestinal haemorrhage (Side Effect) and Gastrointestinal haemorrhage (Side Effect) is caused by Prasugrel (Compound)
Tolmetin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical ef... |
DB00741 | DB06655 | 167 | 5 | [
"DDInter885",
"DDInter1077"
] | Hydrocortisone | Liraglutide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
167,
24,
5
]
],
[
[
167,
63,
743
],
[
743,
23,
5
]
],
[
[
167,
24,
915
],
[
915,
24,
5
]
],
[
[
167,
63,
559
],
[
559,
24,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and... |
DB00193 | DB01183 | 534 | 173 | [
"DDInter1841",
"DDInter1262"
] | Tramadol | Naloxone | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, ... | Moderate | 1 | [
[
[
534,
24,
173
]
],
[
[
534,
25,
475
],
[
475,
24,
173
]
],
[
[
534,
25,
267
],
[
267,
40,
173
]
],
[
[
534,
6,
7940
],
[
7940,
45... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"... | Tramadol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Tramadol may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone (Compound) resembles Naloxone (Comp... |
DB00047 | DB00206 | 176 | 1,245 | [
"DDInter932",
"DDInter1582"
] | Insulin glargine | Reserpine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Moderate | 1 | [
[
[
176,
24,
1245
]
],
[
[
176,
24,
1340
],
[
1340,
1,
1245
]
],
[
[
176,
24,
22
],
[
22,
63,
1245
]
],
[
[
176,
24,
73
],
[
73,
24,... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine and Deserpidine (Compound) resembles Reserpine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction... |
DB01082 | DB09473 | 1,448 | 884 | [
"DDInter1713",
"DDInter918"
] | Streptomycin | Indium In-111 oxyquinoline | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
1448,
24,
884
]
],
[
[
1448,
63,
50
],
[
50,
24,
884
]
],
[
[
1448,
64,
1441
],
[
1441,
24,
884
]
],
[
[
1448,
35,
416
],
[
416,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasa... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Streptomycin may lead to a major life threatening interaction when taken with Bacitracin... |
DB00641 | DB00705 | 467 | 441 | [
"DDInter1675",
"DDInter496"
] | Simvastatin | Delavirdine | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Major | 2 | [
[
[
467,
25,
441
]
],
[
[
467,
6,
21998
],
[
21998,
45,
441
]
],
[
[
467,
21,
28709
],
[
28709,
60,
441
]
],
[
[
467,
63,
63
],
[
63,
... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compo... | Simvastatin (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Delavirdine (Compound)
Simvastatin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Simvastatin may cause a moderate interaction that could exacerbate dis... |
DB06616 | DB06688 | 594 | 1,430 | [
"DDInter224",
"DDInter1677"
] | Bosutinib | Sipuleucel-T | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
594,
24,
1430
]
],
[
[
594,
63,
869
],
[
869,
24,
1430
]
],
[
[
594,
25,
676
],
[
676,
63,
1430
]
],
[
[
594,
24,
713
],
[
713,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may caus... |
DB00087 | DB11569 | 599 | 1,093 | [
"DDInter41",
"DDInter1003"
] | Alemtuzumab | Ixekizumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
599,
24,
1093
]
],
[
[
599,
24,
66
],
[
66,
24,
1093
]
],
[
[
599,
24,
1367
],
[
1367,
63,
1093
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine... |
DB00679 | DB09045 | 684 | 52 | [
"DDInter1796",
"DDInter607"
] | Thioridazine | Dulaglutide | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
684,
24,
52
]
],
[
[
684,
24,
170
],
[
170,
23,
52
]
],
[
[
684,
25,
609
],
[
609,
24,
52
]
],
[
[
684,
63,
73
],
[
73,
24,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Thioridazine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromyc... |
DB00774 | DB08907 | 1,577 | 1,344 | [
"DDInter889",
"DDInter280"
] | Hydroflumethiazide | Canagliflozin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1577,
24,
1344
]
],
[
[
1577,
24,
549
],
[
549,
1,
1344
]
],
[
[
1577,
21,
28873
],
[
28873,
60,
1344
]
],
[
[
1577,
24,
1486
],
[
148... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapaglif... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Hydroflumethiazide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Canagliflozin (Compound)
Hydroflume... |
DB00945 | DB01381 | 1,479 | 958 | [
"DDInter20",
"DDInter819"
] | Acetylsalicylic acid | Ginkgo biloba | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
1479,
24,
958
]
],
[
[
1479,
63,
1347
],
[
1347,
24,
958
]
],
[
[
1479,
64,
126
],
[
126,
24,
958
]
],
[
[
1479,
24,
1039
],
[
1039,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clop... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Warfarin an... |
DB06589 | DB08815 | 1,250 | 154 | [
"DDInter1400",
"DDInter1104"
] | Pazopanib | Lurasidone | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1250,
24,
154
]
],
[
[
1250,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1250,
21,
29402
],
[
29402,
60,
154
]
],
[
[
1250,
24,
1033
],
[
1033... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Pazopanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Pazopanib (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound)
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00280 | DB01234 | 494 | 1,220 | [
"DDInter575",
"DDInter513"
] | Disopyramide | Dexamethasone | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
494,
24,
1220
]
],
[
[
494,
24,
870
],
[
870,
1,
1220
]
],
[
[
494,
24,
175
],
[
175,
40,
1220
]
],
[
[
494,
6,
8374
],
[
8374,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles... |
DB01362 | DB09420 | 497 | 1,074 | [
"DDInter960",
"DDInter953"
] | Iohexol | Iodide I-123 | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
497,
24,
1074
]
],
[
[
497,
64,
50
],
[
50,
24,
1074
]
],
[
[
497,
63,
33
],
[
33,
24,
1074
]
],
[
[
497,
24,
278
],
[
278,
24,
... | [
[
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazi... | Iohexol may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may caus... |
DB09038 | DB09112 | 1,450 | 1,455 | [
"DDInter636",
"DDInter1306"
] | Empagliflozin | Nitrous acid | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1450,
24,
1455
]
],
[
[
1450,
63,
312
],
[
312,
24,
1455
]
],
[
[
1450,
24,
1586
],
[
1586,
63,
1455
]
],
[
[
1450,
63,
1107
],
[
1107... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine... |
DB00653 | DB08890 | 544 | 16 | [
"DDInter1120",
"DDInter1069"
] | Magnesium sulfate | Linaclotide | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Minor | 0 | [
[
[
544,
23,
16
]
],
[
[
544,
63,
355
],
[
355,
23,
16
]
],
[
[
544,
24,
603
],
[
603,
62,
16
]
],
[
[
544,
63,
355
],
[
355,
24,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium ... |
DB00396 | DB09075 | 989 | 498 | [
"DDInter1529",
"DDInter621"
] | Progesterone | Edoxaban | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
989,
25,
498
]
],
[
[
989,
24,
1017
],
[
1017,
63,
498
]
],
[
[
989,
24,
129
],
[
129,
24,
498
]
],
[
[
989,
25,
1456
],
[
1456,
... | [
[
[
"Progesterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatin... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and En... |
DB00916 | DB11718 | 112 | 927 | [
"DDInter1202",
"DDInter640"
] | Metronidazole | Encorafenib | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Minor | 0 | [
[
[
112,
23,
927
]
],
[
[
112,
23,
1247
],
[
1247,
23,
927
]
],
[
[
112,
62,
216
],
[
216,
24,
927
]
],
[
[
112,
23,
495
],
[
495,
2... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Chlorpro... |
DB00477 | DB09045 | 216 | 52 | [
"DDInter363",
"DDInter607"
] | Chlorpromazine | Dulaglutide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
216,
24,
52
]
],
[
[
216,
24,
170
],
[
170,
23,
52
]
],
[
[
216,
24,
609
],
[
609,
24,
52
]
],
[
[
216,
63,
73
],
[
73,
24,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromyc... |
DB00624 | DB11730 | 1,561 | 351 | [
"DDInter1776",
"DDInter1588"
] | Testosterone (topical) | Ribociclib | Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1561,
24,
351
]
],
[
[
1561,
24,
283
],
[
283,
62,
351
]
],
[
[
1561,
24,
372
],
[
372,
24,
351
]
],
[
[
1561,
63,
663
],
[
663,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Testoste... |
DB00361 | DB00673 | 134 | 723 | [
"DDInter1939",
"DDInter112"
] | Vinorelbine | Aprepitant | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
134,
24,
723
]
],
[
[
134,
24,
875
],
[
875,
40,
723
]
],
[
[
134,
6,
8374
],
[
8374,
45,
723
]
],
[
[
134,
5,
11579
],
[
11579,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Vinorelbine (Compound) treats breast cancer (Disease) and ... |
DB01069 | DB06700 | 401 | 643 | [
"DDInter1533",
"DDInter511"
] | Promethazine | Desvenlafaxine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
401,
24,
643
]
],
[
[
401,
63,
1100
],
[
1100,
1,
643
]
],
[
[
401,
21,
28709
],
[
28709,
60,
643
]
],
[
[
401,
24,
1383
],
[
1383,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Promethazine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Desvenlafaxine (Compound)
Promethazine... |
DB00603 | DB01276 | 303 | 123 | [
"DDInter1137",
"DDInter706"
] | Medroxyprogesterone acetate | Exenatide | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
303,
24,
123
]
],
[
[
303,
25,
1476
],
[
1476,
63,
123
]
],
[
[
303,
40,
443
],
[
443,
24,
123
]
],
[
[
303,
63,
1560
],
[
1560,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatini... | Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Medroxyprogesterone acetate (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moder... |
DB01132 | DB14509 | 1,130 | 1,399 | [
"DDInter1472",
"DDInter1081"
] | Pioglitazone | Lithium carbonate | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1130,
24,
1399
]
],
[
[
1130,
63,
874
],
[
874,
23,
1399
]
],
[
[
1130,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
1130,
63,
1674
],
[
1674... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Abirateron... |
DB05316 | DB06663 | 749 | 1,154 | [
"DDInter1467",
"DDInter1398"
] | Pimavanserin | Pasireotide | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
749,
25,
1154
]
],
[
[
749,
62,
112
],
[
112,
23,
1154
]
],
[
[
749,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
749,
63,
480
],
[
480,
... | [
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric a... |
DB06414 | DB08901 | 655 | 1,468 | [
"DDInter703",
"DDInter1492"
] | Etravirine | Ponatinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
655,
24,
1468
]
],
[
[
655,
63,
478
],
[
478,
24,
1468
]
],
[
[
655,
6,
4973
],
[
4973,
45,
1468
]
],
[
[
655,
21,
29024
],
[
29024,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Etravirine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Etravirine (Compound) ca... |
DB01001 | DB01159 | 688 | 419 | [
"DDInter1632",
"DDInter854"
] | Salbutamol | Halothane | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
688,
24,
419
]
],
[
[
688,
6,
8374
],
[
8374,
45,
419
]
],
[
[
688,
62,
112
],
[
112,
23,
419
]
],
[
[
688,
24,
774
],
[
774,
63... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halothane
Salbutamol may cau... |
DB09061 | DB11130 | 1,627 | 407 | [
"DDInter284",
"DDInter1344"
] | Cannabidiol | Opium | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1627,
24,
407
]
],
[
[
1627,
63,
662
],
[
662,
24,
407
]
],
[
[
1627,
24,
1609
],
[
1609,
63,
407
]
],
[
[
1627,
63,
267
],
[
267,
... | [
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and ... |
DB00658 | DB00978 | 965 | 739 | [
"DDInter1663",
"DDInter1084"
] | Sevelamer | Lomefloxacin | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
965,
24,
739
]
],
[
[
965,
24,
945
],
[
945,
40,
739
]
],
[
[
965,
63,
1176
],
[
1176,
1,
739
]
],
[
[
965,
63,
1467
],
[
1467,
... | [
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
[
... | Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (... |
DB01045 | DB01190 | 463 | 568 | [
"DDInter1590",
"DDInter398"
] | Rifampicin | Clindamycin | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
463,
24,
568
]
],
[
[
463,
6,
8374
],
[
8374,
45,
568
]
],
[
[
463,
24,
609
],
[
609,
63,
568
]
],
[
[
463,
25,
384
],
[
384,
63... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Rifampic... |
DB01169 | DB14509 | 57 | 1,399 | [
"DDInter120",
"DDInter1081"
] | Arsenic trioxide | Lithium carbonate | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
57,
25,
1399
]
],
[
[
57,
64,
589
],
[
589,
23,
1399
]
],
[
[
57,
25,
1374
],
[
1374,
24,
1399
]
],
[
[
57,
64,
1010
],
[
1010,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplat... | Arsenic trioxide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Arsenic trioxide may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may caus... |
DB00197 | DB00962 | 1,324 | 1,639 | [
"DDInter1881",
"DDInter1957"
] | Troglitazone | Zaleplon | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Minor | 0 | [
[
[
1324,
23,
1639
]
],
[
[
1324,
24,
891
],
[
891,
23,
1639
]
],
[
[
1324,
23,
1101
],
[
1101,
23,
1639
]
],
[
[
1324,
24,
1220
],
[
1220... | [
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zaleplon"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Zaleplon
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexa... |
DB00635 | DB06710 | 1,573 | 1,546 | [
"DDInter1515",
"DDInter1193"
] | Prednisone | Methyltestosterone | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Moderate | 1 | [
[
[
1573,
35,
1546
]
],
[
[
1573,
40,
1581
],
[
1581,
1,
1546
]
],
[
[
1573,
24,
312
],
[
312,
1,
1546
]
],
[
[
1573,
1,
984
],
[
984,
... | [
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Testolactone"
],
... | Prednisone (Compound) resembles Methyltestosterone (Compound) and
Prednisone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Methyltestosterone (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone (Compound) re... |
DB06414 | DB06595 | 655 | 1,491 | [
"DDInter703",
"DDInter1214"
] | Etravirine | Midostaurin | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
655,
24,
1491
]
],
[
[
655,
24,
1135
],
[
1135,
62,
1491
]
],
[
[
655,
63,
112
],
[
112,
23,
1491
]
],
[
[
655,
63,
761
],
[
761,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metron... |
DB00621 | DB01583 | 1,026 | 624 | [
"DDInter1357",
"DDInter1075"
] | Oxandrolone | Liotrix | A synthetic hormone with anabolic and androgenic properties. | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
1026,
24,
624
]
],
[
[
1026,
63,
1152
],
[
1152,
1,
624
]
],
[
[
1026,
63,
542
],
[
542,
40,
624
]
],
[
[
1026,
21,
28905
],
[
28905,
... | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
... | Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Comp... |
DB01058 | DB12130 | 978 | 1,017 | [
"DDInter1510",
"DDInter1094"
] | Praziquantel | Lorlatinib | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
978,
24,
1017
]
],
[
[
978,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
978,
62,
510
],
[
510,
24,
1017
]
],
[
[
978,
24,
214
],
[
214,
... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Praziquantel may cause a minor interaction that can limit clinical effects when taken with Albendazole and Alben... |
DB00158 | DB00754 | 356 | 157 | [
"DDInter771",
"DDInter696"
] | Folic acid | Ethotoin | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
356,
24,
157
]
],
[
[
356,
24,
759
],
[
759,
40,
157
]
],
[
[
356,
24,
499
],
[
499,
1,
157
]
],
[
[
356,
21,
28787
],
[
28787,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Ethotoin (Compound)
Fo... |
DB00222 | DB00615 | 245 | 690 | [
"DDInter825",
"DDInter1589"
] | Glimepiride | Rifabutin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Moderate | 1 | [
[
[
245,
24,
690
]
],
[
[
245,
24,
463
],
[
463,
1,
690
]
],
[
[
245,
21,
28680
],
[
28680,
60,
690
]
],
[
[
245,
24,
1101
],
[
1101,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Glimepiride (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Rifabutin (Compound)
Glimepiride may cause a moderate interaction that coul... |
DB01097 | DB09115 | 1,377 | 505 | [
"DDInter1033",
"DDInter559"
] | Leflunomide | Diiodohydroxyquinoline | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
1377,
24,
505
]
],
[
[
1377,
25,
1593
],
[
1593,
24,
505
]
],
[
[
1377,
64,
467
],
[
467,
24,
505
]
],
[
[
1377,
24,
1434
],
[
1434,
... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
... | Leflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Leflunomide may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause... |
DB00876 | DB01222 | 1,414 | 617 | [
"DDInter658",
"DDInter246"
] | Eprosartan | Budesonide | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1414,
24,
617
]
],
[
[
1414,
63,
251
],
[
251,
1,
617
]
],
[
[
1414,
24,
1220
],
[
1220,
1,
617
]
],
[
[
1414,
21,
28719
],
[
28719,
... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide... |
DB00900 | DB08865 | 45 | 1,593 | [
"DDInter544",
"DDInter448"
] | Didanosine | Crizotinib | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
45,
24,
1593
]
],
[
[
45,
7,
7310
],
[
7310,
46,
1593
]
],
[
[
45,
6,
4071
],
[
4071,
57,
1593
]
],
[
[
45,
21,
29047
],
[
29047,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Didanosine",
"{u} (Compound) upregulates {v} (Gene)",
"KLHL9"
],
[
"KLHL9",
"{u} (Gene) is upregulated by {v} (C... | Didanosine (Compound) upregulates KLHL9 (Gene) and KLHL9 (Gene) is upregulated by Crizotinib (Compound)
Didanosine (Compound) binds PNP (Gene) and PNP (Gene) is downregulated by Crizotinib (Compound)
Didanosine (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) is caus... |
DB00526 | DB00586 | 1,555 | 1,512 | [
"DDInter1355",
"DDInter537"
] | Oxaliplatin | Diclofenac | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1555,
24,
1512
]
],
[
[
1555,
24,
1263
],
[
1263,
63,
1512
]
],
[
[
1555,
6,
9842
],
[
9842,
45,
1512
]
],
[
[
1555,
24,
479
],
[
479,... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Oxaliplatin (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Diclofenac (Compound)
Oxaliplatin may ca... |
DB00951 | DB08870 | 1,072 | 850 | [
"DDInter986",
"DDInter228"
] | Isoniazid | Brentuximab vedotin | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1072,
24,
850
]
],
[
[
1072,
63,
896
],
[
896,
24,
850
]
],
[
[
1072,
24,
1468
],
[
1468,
63,
850
]
],
[
[
1072,
24,
980
],
[
980,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Po... |
DB00215 | DB00448 | 1,230 | 1,215 | [
"DDInter388",
"DDInter1022"
] | Citalopram | Lansoprazole | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Major | 2 | [
[
[
1230,
25,
1215
]
],
[
[
1230,
25,
660
],
[
660,
1,
1215
]
],
[
[
1230,
6,
8374
],
[
8374,
45,
1215
]
],
[
[
1230,
21,
28882
],
[
28882... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
... | Citalopram may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole (Compound) resembles Lansoprazole (Compound)
Citalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lansoprazole (Compound)
Citalopram (Compound) causes Body temperature increased (Side Effect) and... |
DB00719 | DB00962 | 1,219 | 1,639 | [
"DDInter149",
"DDInter1957"
] | Azatadine | Zaleplon | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
1219,
24,
1639
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
1639
]
],
[
[
1219,
63,
13
],
[
13,
24,
1639
]
],
[
[
1219,
24,
1609
],
[
1609,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zaleplon (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Azatadine may ca... |
DB01364 | DB06292 | 22 | 549 | [
"DDInter650",
"DDInter474"
] | Ephedrine | Dapagliflozin | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
22,
24,
549
]
],
[
[
22,
24,
1344
],
[
1344,
40,
549
]
],
[
[
22,
21,
28882
],
[
28882,
60,
549
]
],
[
[
22,
63,
1630
],
[
1630,
... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Ephedrine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dapagliflozin (Compound)
... |
DB00694 | DB11901 | 51 | 913 | [
"DDInter485",
"DDInter107"
] | Daunorubicin | Apalutamide | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
51,
24,
913
]
],
[
[
51,
23,
112
],
[
112,
23,
913
]
],
[
[
51,
63,
600
],
[
600,
24,
913
]
],
[
[
51,
24,
1237
],
[
1237,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole an... |
DB01101 | DB04845 | 60 | 309 | [
"DDInter285",
"DDInter1001"
] | Capecitabine | Ixabepilone | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Minor | 0 | [
[
[
60,
23,
309
]
],
[
[
60,
5,
11579
],
[
11579,
44,
309
]
],
[
[
60,
21,
28736
],
[
28736,
60,
309
]
],
[
[
60,
63,
1419
],
[
1419,
... | [
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixabepilone"
]
],
[
[
"Capecitabine",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is t... | Capecitabine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Ixabepilone (Compound)
Capecitabine (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Capecitabine may cause a moderate interaction that could exacerbate diseases ... |
DB01166 | DB11652 | 477 | 1,155 | [
"DDInter379",
"DDInter1891"
] | Cilostazol | Tucatinib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
477,
25,
1155
]
],
[
[
477,
63,
222
],
[
222,
23,
1155
]
],
[
[
477,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
477,
24,
659
],
[
659,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramin... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ma... |
DB01067 | DB01138 | 959 | 804 | [
"DDInter826",
"DDInter1726"
] | Glipizide | Sulfinpyrazone | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
959,
24,
804
]
],
[
[
959,
63,
998
],
[
998,
1,
804
]
],
[
[
959,
6,
8374
],
[
8374,
45,
804
]
],
[
[
959,
63,
168
],
[
168,
23,... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfinpyrazone (Compound)
Glipizide may cause a moderate interaction that coul... |
DB00651 | DB01203 | 746 | 699 | [
"DDInter613",
"DDInter1255"
] | Dyphylline | Nadolol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Major | 2 | [
[
[
746,
25,
699
]
],
[
[
746,
25,
729
],
[
729,
1,
699
]
],
[
[
746,
21,
28722
],
[
28722,
60,
699
]
],
[
[
746,
23,
22
],
[
22,
63... | [
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nadolol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Com... | Dyphylline may lead to a major life threatening interaction when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Dyphylline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Nadolol (Compound)
Dyphylline may cause a minor interaction that can limit clinical effect... |
DB01142 | DB11130 | 1,264 | 407 | [
"DDInter593",
"DDInter1344"
] | Doxepin | Opium | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1264,
24,
407
]
],
[
[
1264,
63,
558
],
[
558,
24,
407
]
],
[
[
1264,
24,
1190
],
[
1190,
24,
407
]
],
[
[
1264,
64,
529
],
[
529,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause a mo... |
DB00703 | DB06203 | 997 | 1,002 | [
"DDInter1167",
"DDInter51"
] | Methazolamide | Alogliptin | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
997,
24,
1002
]
],
[
[
997,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
997,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
997,
21,
29340
],
[
2934... | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Methazolamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Methazolamide (Compound) causes Stevens-Johnson syndrome (... |
DB00679 | DB00889 | 684 | 1,133 | [
"DDInter1796",
"DDInter840"
] | Thioridazine | Granisetron | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
684,
25,
1133
]
],
[
[
684,
63,
19
],
[
19,
40,
1133
]
],
[
[
684,
63,
85
],
[
85,
1,
1133
]
],
[
[
684,
6,
12523
],
[
12523,
45... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyos... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compou... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.